Pluri
Business Services · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building No. 5 Matam Advanced Technology...Phone Number
+972 747108600Website
www.pluri-biotech.comRevenue
<$5 MillionStock Symbol
PLURIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Pluri
Pluri Inc. is a biotechnology company focused on developing scalable cell-based technologies for applications in healthcare, food production, and agriculture. The company uses proprietary cell expansion platforms to grow and manufacture biological cells that can be used in regenerative medicine, sustainable food solutions, and other advanced biotechnology applications through partnerships and research initiatives.Explore more
Pluri Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pluri your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Pluri recently announced quarterly report
Click to see if Pluri had a recent Job posting/layoffs
Product Launch: Get notified when Pluri launches new products
Funding: Get notified immidiatlly once Pluri has new funding data
Check out if Pluri is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Pluri has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Pluri
Pluri, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Pluri
Find 2 more new buyers
Company Profile Activity
Activity Insights
Pluri is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Pluri is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Pluri.
Pluri financials insights
Gather financial insights about Pluri, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Other Financing Round
$6.5M
Other Financing Round
$3.5M
Pluri Tech Stack
A closer look at the technologies used by Pluri
See more technologies
Most Recent Scoops
Partnership
Partnership, Engineering, Research & Development, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Person-Based
Pluri News & Media
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In
We just covered the 7 Best Lab-Grown Meat Stocks to Invest In and Pluri Inc. (NASDAQ:PLUR) ranks 4th on this list. Pluri Inc. (NASDAQ:PLUR), through the highly publicized joint venture, Ever After Foods, utilizes proprietary, state-of-the-art 3D bioreactor systems to cultivate animal cells with unprecedented density and cost efficiency. While most cell-cultured companies struggle with […]Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company’s largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to thePluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has granted Pluri Biotech Ltd., a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune cell expansion and activation tPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD (“Resbiomed”), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pluri
Sign Up For FreeTo access detailed company insights
Pluri Inc. is a biotechnology company focused on developing scalable cell-based technologies for applications in healthcare, food production, and agriculture. The company uses proprietary cell expansion platforms to grow and manufacture biological cells that can be used in regenerative medicine, sustainable food solutions, and other advanced biotec... Read More
